Internal Medicine Residency.
Gastroenterology Department, University of Massachusetts Medical Memorial Center, Worcester, Massachusetts, USA.
Curr Opin Gastroenterol. 2019 Nov;35(6):517-523. doi: 10.1097/MOG.0000000000000582.
Upper gastrointestinal bleeding (UGIB) is a common and life-threatening condition in the United States and worldwide.
There have been several exciting recent advances in the endoscopic management of UGIB. One such advance is the recent approval of Hemospray by US Food and Drug Administration in May 2018. Another one is the emerging role of video capsule endoscopy as a triage and localization tool for UGIB patients. Finally, the development of new reversal agents for antithrombotic medications is an important advance in the management of life-threatening upper gastrointestinal bleed.
In this article, we will broadly review the management of nonvariceal UGIB, focusing primarily on the data addressing these new advances.
上消化道出血（UGIB）是美国和全球范围内常见且危及生命的病症。
在 UGIB 的内镜治疗方面，最近有一些令人兴奋的进展。其中一项进展是 2018 年 5 月美国食品和药物管理局批准了 Hemospray。另一项进展是视频胶囊内镜在 UGIB 患者的分诊和定位中的新作用。最后，新型抗血栓药物逆转剂的开发是治疗危及生命的上消化道出血的重要进展。
本文将广泛综述非静脉曲张性 UGIB 的治疗方法，主要关注这些新进展的数据。
